{
    "clinical_study": {
        "@rank": "60449", 
        "arm_group": [
            {
                "arm_group_label": "Iron infusion", 
                "arm_group_type": "Experimental", 
                "description": "Iron Sucrose (Venofer (R))"
            }, 
            {
                "arm_group_label": "Normal saline infusion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Equal volume to intervention of normal saline"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate whether the treatment of non-anemic iron deficiency\n      with intervenous iron sucrose will result in decreased symptom reporting and improved\n      cardiovascular indices in adolescents (age 12-18) with Postural Orthostatic Tachycardia\n      Syndrome (POTS)."
        }, 
        "brief_title": "Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Postural Orthostatic Tachycardia Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Tachycardia", 
                "Anemia, Iron-Deficiency", 
                "Postural Orthostatic Tachycardia Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  aged 12-18 years\n\n          -  chronic (>3 months)symptoms of orthostatic intolerance (including but not limited to\n             lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and\n             palpitations)\n\n          -  symptomatic orthostatic heart rate increase of greater than or equal to 40 beats per\n             minute during a 10 minute 70 degree head up tilt study\n\n          -  presence of non-anemic iron deficiency, defined as serum ferritin level less than or\n             equal to 12 ug/L with normal hemoglobin\n\n        Exclusion criteria\n\n          -  orthostatic hypotension within 3 minutes of 70 degree head up tilt\n\n          -  pregnant or lactating females\n\n          -  presence of other organ failure or systemic illness that can affect autonomic\n             function\n\n          -  concurrent medication therapy with anticholinergic, alpha-adrenergic antagonists,\n             beta-adrenergic antagonists unless medication is held for five half-lives prior to\n             study\n\n          -  laboratory evidence of anemia or iron overload\n\n          -  personal history of hematochromatosis or first degree relative with hematochromatosis\n\n          -  known sensitivity to Venofer (TM) or other intravenous iron preparations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978535", 
            "org_study_id": "12-009963"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iron infusion", 
                "description": "5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg.  Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.", 
                "intervention_name": "Iron infusion", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Iron sucrose", 
                    "Venofer (TM)"
                ]
            }, 
            {
                "arm_group_label": "Normal saline infusion", 
                "description": "Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL", 
                "intervention_name": "Normal saline infusion", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Normal saline", 
                    "NaCl 0.9%"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ferric oxide, saccharated", 
                "Ferric Compounds", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "POTS", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "last_name": "Tonette Gehrking", 
                "phone": "507-284-4462"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Amie Jones, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study will assess whether a single infusion of iron sucrose will improve cardiovascular indices, specifically a reduction in the intraval of measured heart rate change, during a ten minute head up tilt, in adolescent subjects with POTS and non-anemic iron deficiency", 
            "measure": "Cardiovascular indices-Intraval change in heart rate during 10-minute head up tilt table test", 
            "safety_issue": "No", 
            "time_frame": "7 (+/- 2) days following intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978535"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Amie E. Jones, M.D.", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}